Forestalling BRAF-Inhibitor Resistance in a Shocking Way.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29980533.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1344.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting BRAF in <i>BRAF</i>-mutant melanoma is highly effective, but most patients develop resistance. HSP90 has been implicated and identified as a therapeutic target. Ultimately, early-stage clinical investigation will be necessary to provide proof of principle of this approach and if appropriate randomized trials to confirm promising findings. <i>Clin Cancer Res; 24(22); 5496-8. ©2018 AACR</i> <i>See related article by Eroglu et al., p. 5516</i>.
Medical subject headings
- Melanoma
- Proto-Oncogene Proteins B-raf